Abstract
Physiological enzymatic cleavage of membrane phospholipids by phospholipase A2 (PLA2) results in normal levels of phosphomonoester and phosphodiester, by which a normal dopamine neurotransmission is maintained. Data from postmortem tissue and in vivo imaging studies suggest that increased activity of intracellular calcium-independent PLA2 (iPLA2) in the brain of schizophrenic patients might accelerate the breakdown of membrane phospholipids and alter the properties of neuronal membranes, which in turn contributes to a hypodopaminergy. Alterations in PLA2 activity are probably genetically determined and represent a possible pharmacological target for Schizophrenia.
Keywords: schizophrenia, neuroimaging, membrane, phospholipase A2, dopamine
Current Topics in Medicinal Chemistry
Title:Alterations of Brain Membranes in Schizophrenia: Impact of Phospholipase A2
Volume: 12 Issue: 21
Author(s): E.L. Schaeffer, W.F. Gattaz and G.P. Eckert
Affiliation:
Keywords: schizophrenia, neuroimaging, membrane, phospholipase A2, dopamine
Abstract: Physiological enzymatic cleavage of membrane phospholipids by phospholipase A2 (PLA2) results in normal levels of phosphomonoester and phosphodiester, by which a normal dopamine neurotransmission is maintained. Data from postmortem tissue and in vivo imaging studies suggest that increased activity of intracellular calcium-independent PLA2 (iPLA2) in the brain of schizophrenic patients might accelerate the breakdown of membrane phospholipids and alter the properties of neuronal membranes, which in turn contributes to a hypodopaminergy. Alterations in PLA2 activity are probably genetically determined and represent a possible pharmacological target for Schizophrenia.
Export Options
About this article
Cite this article as:
Schaeffer E.L., Gattaz W.F. and Eckert G.P., Alterations of Brain Membranes in Schizophrenia: Impact of Phospholipase A2, Current Topics in Medicinal Chemistry 2012; 12 (21) . https://dx.doi.org/10.2174/1568026611212210004
DOI https://dx.doi.org/10.2174/1568026611212210004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Improvement of Learning and Increase in Dopamine Level in the Frontal Cortex by Methylphenidate in Mice Lacking Dopamine Transporter
Current Molecular Medicine New Frontiers in Alcoholism and Addiction Treatment
Recent Patents on CNS Drug Discovery (Discontinued) Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD
Current Alzheimer Research Magnetic Resonance Imaging of Iron in Parkinsons Disease
Current Medical Imaging Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Bivalent Ligands for G Protein-Coupled Receptors
Current Pharmaceutical Design Brain Perfusion SPECT with Brodmann Areas Analysis in Differentiating Frontotemporal Dementia Subtypes
Current Alzheimer Research Oxidative Stress: Major Threat in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry Targeting of Peripherally Expressed Pain-Related Molecules in Injury- Induced Chronic Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Augmentation Strategies to Improve Treatment of Major Depression
Central Nervous System Agents in Medicinal Chemistry Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Advances in the Understanding of the Cannabinoid Receptor 1 – Focusing on the Inverse Agonists Interactions
Current Medicinal Chemistry Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Polymorphisms at the LDLR Locus may be Associated with Ischemic Cerebrovascular Disease Independent of Lipid Profile
Current Neurovascular Research Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine